Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial.

ABSTRACT:

SUBMITTER: Gurumurthi A 

PROVIDER: S-EPMC11332795 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature